Surgical crossroads: what to do after tube-shunt failure

Article

Glaucoma implants may fail for a number of reasons, said Felix Gil Carrasco, MD, at the World Congress of Ophthalmology on Wednesday. However, inappropriate patient selection and improper placement of the shunt are probably the most common reasons.

Glaucoma implants may fail for a number of reasons, said Felix Gil Carrasco, MD, at the World Congress of Ophthalmology on Wednesday. However, inappropriate patient selection and improper placement of the shunt are probably the most common reasons.

Tube implants should be only for certain types of patients, like those with neovascular or inflammatory glaucoma, and those who require a careful assessment to discard a thin or softened sclera or a fibrotic conjunctiva. Implants should be avoided when the anterior chamber is non-existent or too narrow, or if there is a closed angle and in nanophthalmos.

"The mental state is also of particular importance, as the implantation will require changes in lifestyle and special care," added Dr. Gil of the Federal University of Sao Paulo and president of the Pan-American Society of Glaucoma. "Future complications are likely if these conditions are ignored - for example in a patient who, against the ophthalmologist's indication, scratches his eye continually due to itching. An expected result might be corneal edema."

Other causes for shunt failure include contact with the endothelium, placement over the iris, and displacements. A narrow chamber, a long tube, or both must be corrected. The tube may also become occluded by fibrin or silicon. This may be rectified using a N:YAG laser, or with mechanical correction. Extrusion is another possible complication. If only partial, Dr. Gil recommended observation, lubrication, and use of antibiotics. In severe cases, removal and reimplantation may be necessary.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.